Topical Dorzolamide-Timolol Beneficial in Neovascular AMD

This article originally appeared here.
Share this content:
Topical Dorzolamide-Timolol Beneficial in Neovascular AMD
Topical Dorzolamide-Timolol Beneficial in Neovascular AMD

FRIDAY, Feb. 26, 2016 (HealthDay News) -- Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response to anti-vascular endothelial growth factor (VEGF) therapy, according to a study published online Feb. 25 in JAMA Ophthalmology.

Jayanth Sridhar, M.D., from the Thomas Jefferson University in Philadelphia, and colleagues conducted a prospective single-arm interventional study involving patients with neovascular AMD and persistent macular edema despite fixed-interval intravitreous anti-VEGF therapy. Ten patients (mean age, 78.2 years) with 10 affected eyes received a regimen of topical dorzolamide-timolol twice daily and the same intravitreous anti-VEGF therapy, administered at the same interval as before enrollment. Eight patients received intravitreous aflibercept and two received intravitreous ranibizumab.

The researchers observed a decrease in mean central subfield thickness from 419.7 µm at enrollment to 334.1 µm at the final visit (P = 0.01). From enrollment to the last visit there was also a decrease in mean maximum subretinal fluid height (from 126.6 to 49.5 µm; P = 0.02). From enrollment to the final visit there were nonsignificant decreases in the mean maximum pigment epithelial detachment height (P = 0.12) and the mean logMAR visual acuity (P = 0.60).

"These data suggest that topical dorzolamide-timolol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despite consistent, fixed-interval intravitreous anti-VEGF treatment for neovascular AMD," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »